4.38
-0.11(-2.45%)
Currency In USD
| Previous Close | 4.49 |
| Open | 4.49 |
| Day High | 4.49 |
| Day Low | 4.36 |
| 52-Week High | 7.73 |
| 52-Week Low | 2.9 |
| Volume | 4.12M |
| Average Volume | 4.99M |
| Market Cap | 386.57M |
| PE | -4.09 |
| EPS | -1.07 |
| Moving Average 50 Days | 4.7 |
| Moving Average 200 Days | 4.55 |
| Change | -0.11 |
If you invested $1000 in Altimmune, Inc. (ALT) since IPO date, it would be worth $32.88 as of February 21, 2026 at a share price of $4.38. Whereas If you bought $1000 worth of Altimmune, Inc. (ALT) shares 5 years ago, it would be worth $223.93 as of February 21, 2026 at a share price of $4.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 29, 2026 10:54 PM GMT
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced register
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 28, 2026 2:25 AM GMT
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purc
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
GlobeNewswire Inc.
Jan 05, 2026 12:30 PM GMT
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDAGAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharma